Susquehanna Portfolio Strategies LLC Has $207,000 Stock Position in Kodiak Sciences Inc. (NASDAQ:KOD)

Susquehanna Portfolio Strategies LLC decreased its position in shares of Kodiak Sciences Inc. (NASDAQ:KOD) by 14.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 88,016 shares of the company’s stock after selling 14,353 shares during the period. Susquehanna Portfolio Strategies LLC owned 0.17% of Kodiak Sciences worth $207,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of KOD. American Century Companies Inc. boosted its holdings in shares of Kodiak Sciences by 18.5% during the 2nd quarter. American Century Companies Inc. now owns 54,323 shares of the company’s stock worth $128,000 after buying an additional 8,470 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Kodiak Sciences in the first quarter valued at about $50,000. Vanguard Group Inc. increased its stake in shares of Kodiak Sciences by 0.7% in the first quarter. Vanguard Group Inc. now owns 1,654,448 shares of the company’s stock worth $8,702,000 after purchasing an additional 10,978 shares during the period. Nan Fung Group Holdings Ltd lifted its position in shares of Kodiak Sciences by 62.7% during the 1st quarter. Nan Fung Group Holdings Ltd now owns 31,922 shares of the company’s stock worth $168,000 after purchasing an additional 12,300 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Kodiak Sciences during the 1st quarter valued at approximately $68,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $3.00 price target on shares of Kodiak Sciences in a research report on Tuesday, September 24th. Two analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, Kodiak Sciences currently has a consensus rating of “Hold” and a consensus price target of $5.00.

Kodiak Sciences Stock Performance

Shares of KOD opened at $2.66 on Monday. The company has a 50-day simple moving average of $2.65 and a 200-day simple moving average of $3.26. Kodiak Sciences Inc. has a 52 week low of $1.37 and a 52 week high of $7.77. The firm has a market capitalization of $139.74 million, a P/E ratio of -0.60 and a beta of 2.35.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.86) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.01. As a group, equities analysts forecast that Kodiak Sciences Inc. will post -3.52 earnings per share for the current year.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.